GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6699 ArvanilSummary: Cannabinoid CB1 and vanilloid TRPV1 (VR1) agonist -
B6703 VUF 5574Summary: human adenosine A3 receptor antagonist -
B6705 PD 81723Summary: Allosteric potentiator at the adenosine A1 receptor -
B6708 SB 204741Summary: 5-HT2B receptor antagonist -
B6709 SB 228357Summary: 5-HT2C/2B receptor antagonist -
B6710 SB 218795Summary: NK3 receptor antagonist -
B6713 SB 221284Summary: 5-HT2C/2B receptor antagonist -
B6714 L-152,804Summary: neuropeptide Y Y5 receptor antagonist -
B6722 SCH 202676 hydrobromideSummary: inhibitor of both agonist and antagonist binding to diverse GPCRs -
B6725 YM 022Summary: CCK2 silent antagonist

